Potentiation of EO9 anti-tumour activity by hydralazine

This publication has 10 references indexed in Scilit:

• Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents
  International Journal of Radiation Oncology*Biology*Physics, 1992
• Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice
  British Journal of Cancer, 1992
• In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity
  British Journal of Cancer, 1992
• The Role of NAD(P)H: Quinone Reductase (EC 1.6.99.2, DT-Diaphorase) in the Reductive Bioactivation of the Novel Indoloquinone Antitumor Agent E09
  Cancer Communications, 1991
• Effects of Two Tumour Blood Flow Modifiers, Hydralazine and Flavone Acetic Acid, on KHT Tumours and Normal Tissues in Mice
  International Journal of Radiation Biology, 1991
• Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC 347512)
  British Journal of Cancer, 1988
• The logistics of broader pre-clinical evaluation of potential anti-cancer agents with reference to anti-tumour activity and toxicity of mitozolomide
  British Journal of Cancer, 1988
• The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: Evidence for therapeutic gain
  International Journal of Radiation Oncology*Biology*Physics, 1987
• Mitomycin analogs I. Indoloquinones as (potential) bisalkylating agents
  Tetrahedron, 1987
• Potential bioreductive alkylating agents. 1. Benzoquinone derivatives
  Journal of Medicinal Chemistry, 1972